Access the full text.
Sign up today, get DeepDyve free for 14 days.
D. Simon, C. Tanner, P. Brundin (2020)
Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology.Clinics in geriatric medicine, 36 1
( Katsaiti I , Nixon J (2018) Are there benefits in adding catechol-O methyltransferase inhibitors in the pharmacotherapy of Parkinson’s disease patients? A systematic review. J Parkinsons Dis 8, 217–231.29614697)
Katsaiti I , Nixon J (2018) Are there benefits in adding catechol-O methyltransferase inhibitors in the pharmacotherapy of Parkinson’s disease patients? A systematic review. J Parkinsons Dis 8, 217–231.29614697Katsaiti I , Nixon J (2018) Are there benefits in adding catechol-O methyltransferase inhibitors in the pharmacotherapy of Parkinson’s disease patients? A systematic review. J Parkinsons Dis 8, 217–231.29614697, Katsaiti I , Nixon J (2018) Are there benefits in adding catechol-O methyltransferase inhibitors in the pharmacotherapy of Parkinson’s disease patients? A systematic review. J Parkinsons Dis 8, 217–231.29614697
S. Fox, R. Katzenschlager, Shen-Yang Lim, B. Barton, R. Bie, K. Seppi, M. Coelho, C. Sampaio (2018)
International Parkinson and movement disorder society evidence‐based medicine review: Update on treatments for the motor symptoms of Parkinson's diseaseMovement Disorders, 33
G. Wooten, L. Currie, V. Bovbjerg, J. Lee, J. Patrie (2004)
Are men at greater risk for Parkinson’s disease than women?Journal of Neurology, Neurosurgery & Psychiatry, 75
J. Ferreira, A. Lees, J. Rocha, W. Poewe, O. Rascol, P. Soares-da-Silva (2019)
Long‐term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open‐label extensionsEuropean Journal of Neurology, 26
( Feldman M , Margolesky J (2021) Opicapone for the treatment of Parkinson’s disease: a review. Int J Neurosci. doi: 10.1080/00207454.2021.1929217.)
Feldman M , Margolesky J (2021) Opicapone for the treatment of Parkinson’s disease: a review. Int J Neurosci. doi: 10.1080/00207454.2021.1929217.Feldman M , Margolesky J (2021) Opicapone for the treatment of Parkinson’s disease: a review. Int J Neurosci. doi: 10.1080/00207454.2021.1929217., Feldman M , Margolesky J (2021) Opicapone for the treatment of Parkinson’s disease: a review. Int J Neurosci. doi: 10.1080/00207454.2021.1929217.
J. Lee (2019)
Pharmacological Treatment in Parkinson’s DiseaseJournal of the Korean Neurological Association
( Greenwood J , Pham H , Rey J (2021) Opicapone: A third generation COMT inhibitor. Clin Parkinsonism Relat Disord 4, 100083.)
Greenwood J , Pham H , Rey J (2021) Opicapone: A third generation COMT inhibitor. Clin Parkinsonism Relat Disord 4, 100083.Greenwood J , Pham H , Rey J (2021) Opicapone: A third generation COMT inhibitor. Clin Parkinsonism Relat Disord 4, 100083., Greenwood J , Pham H , Rey J (2021) Opicapone: A third generation COMT inhibitor. Clin Parkinsonism Relat Disord 4, 100083.
( Wooten GF , Currie LJ , Bovbjerg VE , Lee JK , Patrie J (2004) Are men at greater risk for Parkinson’s disease than women? J Neurol Neurosurg Psychiatry 75, 637–639.15026515)
Wooten GF , Currie LJ , Bovbjerg VE , Lee JK , Patrie J (2004) Are men at greater risk for Parkinson’s disease than women? J Neurol Neurosurg Psychiatry 75, 637–639.15026515Wooten GF , Currie LJ , Bovbjerg VE , Lee JK , Patrie J (2004) Are men at greater risk for Parkinson’s disease than women? J Neurol Neurosurg Psychiatry 75, 637–639.15026515, Wooten GF , Currie LJ , Bovbjerg VE , Lee JK , Patrie J (2004) Are men at greater risk for Parkinson’s disease than women? J Neurol Neurosurg Psychiatry 75, 637–639.15026515
( Lees AJ (2008) Evidence-based efficacy comparison of tolcapone and entacapone as adjunctive therapy in Parkinson’s disease. CNS Neurosci Ther 14, 83–93.18482101)
Lees AJ (2008) Evidence-based efficacy comparison of tolcapone and entacapone as adjunctive therapy in Parkinson’s disease. CNS Neurosci Ther 14, 83–93.18482101Lees AJ (2008) Evidence-based efficacy comparison of tolcapone and entacapone as adjunctive therapy in Parkinson’s disease. CNS Neurosci Ther 14, 83–93.18482101, Lees AJ (2008) Evidence-based efficacy comparison of tolcapone and entacapone as adjunctive therapy in Parkinson’s disease. CNS Neurosci Ther 14, 83–93.18482101
A. Takeda, R. Takahashi, Y. Tsuboi, M. Nomoto, T. Maeda, A. Nishimura, Kazuo Yoshida, N. Hattori (2021)
Long-term safety and efficacy of opicapone in Japanese Parkinson’s patients with motor fluctuationsJournal of Neural Transmission, 128
Zhaoming Song, J Zhang, Tao Xue, Yanbo Yang, Da Wu, Zhouqing Chen, Wanchun You, Zhong Wang (2021)
Different Catechol-O-Methyl Transferase Inhibitors in Parkinson's Disease: A Bayesian Network Meta-AnalysisFrontiers in Neurology, 12
( Rivest J , Barclay CL , Suchowersky O (1999) COMT inhibitors in Parkinson’s disease. Can J Neurol Sci 26 Suppl 2, S34–38.10451758)
Rivest J , Barclay CL , Suchowersky O (1999) COMT inhibitors in Parkinson’s disease. Can J Neurol Sci 26 Suppl 2, S34–38.10451758Rivest J , Barclay CL , Suchowersky O (1999) COMT inhibitors in Parkinson’s disease. Can J Neurol Sci 26 Suppl 2, S34–38.10451758, Rivest J , Barclay CL , Suchowersky O (1999) COMT inhibitors in Parkinson’s disease. Can J Neurol Sci 26 Suppl 2, S34–38.10451758
( Takeda A , Takahashi R , Tsuboi Y , Nomoto M , Maeda T , Nishimura A , Yoshida K , Hattori N (2021) Long-term safety and efficacy of opicapone in Japanese Parkinson’s patients with motor fluctuations. J Neural Transm 128, 337–344.33630140)
Takeda A , Takahashi R , Tsuboi Y , Nomoto M , Maeda T , Nishimura A , Yoshida K , Hattori N (2021) Long-term safety and efficacy of opicapone in Japanese Parkinson’s patients with motor fluctuations. J Neural Transm 128, 337–344.33630140Takeda A , Takahashi R , Tsuboi Y , Nomoto M , Maeda T , Nishimura A , Yoshida K , Hattori N (2021) Long-term safety and efficacy of opicapone in Japanese Parkinson’s patients with motor fluctuations. J Neural Transm 128, 337–344.33630140, Takeda A , Takahashi R , Tsuboi Y , Nomoto M , Maeda T , Nishimura A , Yoshida K , Hattori N (2021) Long-term safety and efficacy of opicapone in Japanese Parkinson’s patients with motor fluctuations. J Neural Transm 128, 337–344.33630140
( Kim S , Park J , Seo H , Lee Y , Jang B , Son H , Suh H , Shin C (2011) NECA’s guidance for undertaking systematic reviews and meta-analyses for intervention. National Evidence-Based Healthcare Collaborating Agency, Seoul.)
Kim S , Park J , Seo H , Lee Y , Jang B , Son H , Suh H , Shin C (2011) NECA’s guidance for undertaking systematic reviews and meta-analyses for intervention. National Evidence-Based Healthcare Collaborating Agency, Seoul.Kim S , Park J , Seo H , Lee Y , Jang B , Son H , Suh H , Shin C (2011) NECA’s guidance for undertaking systematic reviews and meta-analyses for intervention. National Evidence-Based Healthcare Collaborating Agency, Seoul., Kim S , Park J , Seo H , Lee Y , Jang B , Son H , Suh H , Shin C (2011) NECA’s guidance for undertaking systematic reviews and meta-analyses for intervention. National Evidence-Based Healthcare Collaborating Agency, Seoul.
( Scott LJ (2016) Opicapone: a review in Parkinson’s disease. Drugs 76, 1293–1300.27498199)
Scott LJ (2016) Opicapone: a review in Parkinson’s disease. Drugs 76, 1293–1300.27498199Scott LJ (2016) Opicapone: a review in Parkinson’s disease. Drugs 76, 1293–1300.27498199, Scott LJ (2016) Opicapone: a review in Parkinson’s disease. Drugs 76, 1293–1300.27498199
J. Greenwood, Huy Pham, J. Rey (2020)
Opicapone: A third generation COMT inhibitorClinical Parkinsonism & Related Disorders, 4
S. Marsala, M. Gioulis, R. Ceravolo, M. Tinazzi (2012)
A Systematic Review of Catechol-O-Methyltransferase Inhibitors: Efficacy and Safety in Clinical PracticeClinical Neuropharmacology, 35
M. Borenstein, L. Hedges, J. Higgins, H. Rothstein (2010)
A basic introduction to fixed‐effect and random‐effects models for meta‐analysisResearch Synthesis Methods, 1
J. Ferreira, A. Lees, W. Poewe, O. Rascol, J. Rocha, B. Keller, P. Soares-da-Silva (2018)
Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson diseaseNeurology, 90
A. Lees, J. Ferreira, J. Rocha, O. Rascol, W. Poewe, P. Soares-da-Silva (2019)
Safety Profile of Opicapone in the Management of Parkinson's Disease.Journal of Parkinson's disease
( Maserejian N , Vinikoor-Imler L , Dilley A (2020) Estimation of the 2020 global population of Parkinson’s disease (PD) [abstract]. Mov Disord 35, 198.)
Maserejian N , Vinikoor-Imler L , Dilley A (2020) Estimation of the 2020 global population of Parkinson’s disease (PD) [abstract]. Mov Disord 35, 198.Maserejian N , Vinikoor-Imler L , Dilley A (2020) Estimation of the 2020 global population of Parkinson’s disease (PD) [abstract]. Mov Disord 35, 198., Maserejian N , Vinikoor-Imler L , Dilley A (2020) Estimation of the 2020 global population of Parkinson’s disease (PD) [abstract]. Mov Disord 35, 198.
( Deane KH , Spieker S , Clarke CE (2004) Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson’s disease. Cochrane Database Syst Rev CD004554.15495119)
Deane KH , Spieker S , Clarke CE (2004) Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson’s disease. Cochrane Database Syst Rev CD004554.15495119Deane KH , Spieker S , Clarke CE (2004) Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson’s disease. Cochrane Database Syst Rev CD004554.15495119, Deane KH , Spieker S , Clarke CE (2004) Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson’s disease. Cochrane Database Syst Rev CD004554.15495119
( Fabbri M , Ferreira JJ , Lees A , Stocchi F , Poewe W , Tolosa E , Rascol O (2018) Opicapone for the treatment of Parkinson’s disease: A review of a new licensed medicine. Mov Disord 33, 1528–1539.30264443)
Fabbri M , Ferreira JJ , Lees A , Stocchi F , Poewe W , Tolosa E , Rascol O (2018) Opicapone for the treatment of Parkinson’s disease: A review of a new licensed medicine. Mov Disord 33, 1528–1539.30264443Fabbri M , Ferreira JJ , Lees A , Stocchi F , Poewe W , Tolosa E , Rascol O (2018) Opicapone for the treatment of Parkinson’s disease: A review of a new licensed medicine. Mov Disord 33, 1528–1539.30264443, Fabbri M , Ferreira JJ , Lees A , Stocchi F , Poewe W , Tolosa E , Rascol O (2018) Opicapone for the treatment of Parkinson’s disease: A review of a new licensed medicine. Mov Disord 33, 1528–1539.30264443
( Ferreira JJ , Lees AJ , Poewe W , Rascol O , Rocha J-F , Keller B , Soares-da-Silva P (2018) Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease. Neurology 90, e1849–e1857.29695590)
Ferreira JJ , Lees AJ , Poewe W , Rascol O , Rocha J-F , Keller B , Soares-da-Silva P (2018) Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease. Neurology 90, e1849–e1857.29695590Ferreira JJ , Lees AJ , Poewe W , Rascol O , Rocha J-F , Keller B , Soares-da-Silva P (2018) Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease. Neurology 90, e1849–e1857.29695590, Ferreira JJ , Lees AJ , Poewe W , Rascol O , Rocha J-F , Keller B , Soares-da-Silva P (2018) Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease. Neurology 90, e1849–e1857.29695590
( Gordin A , Kaakkola S , Teravainen H (2004) Clinical advantages of COMT inhibition with entacapone - a review. J Neural Transm 111, 1343–1363.15340869)
Gordin A , Kaakkola S , Teravainen H (2004) Clinical advantages of COMT inhibition with entacapone - a review. J Neural Transm 111, 1343–1363.15340869Gordin A , Kaakkola S , Teravainen H (2004) Clinical advantages of COMT inhibition with entacapone - a review. J Neural Transm 111, 1343–1363.15340869, Gordin A , Kaakkola S , Teravainen H (2004) Clinical advantages of COMT inhibition with entacapone - a review. J Neural Transm 111, 1343–1363.15340869
A. Takeda, R. Takahashi, Y. Tsuboi, M. Nomoto, T. Maeda, A. Nishimura, Kazuo Yoshida, N. Hattori (2020)
Randomized, Controlled Study of Opicapone in Japanese Parkinson's Patients with Motor FluctuationsMovement Disorders, 36
J. Brotchie, J. Lee, K. Venderová (2005)
Levodopa-induced dyskinesia in Parkinson’s diseaseJournal of Neural Transmission, 112
( Borenstein M , Hedges LV , Higgins JP , Rothstein HR (2010) A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods 1, 97–111.26061376)
Borenstein M , Hedges LV , Higgins JP , Rothstein HR (2010) A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods 1, 97–111.26061376Borenstein M , Hedges LV , Higgins JP , Rothstein HR (2010) A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods 1, 97–111.26061376, Borenstein M , Hedges LV , Higgins JP , Rothstein HR (2010) A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods 1, 97–111.26061376
( Fox SH , Katzenschlager R , Lim SY , Barton B , de Bie RMA , Seppi K , Coelho M , Sampaio C ; Movement Disorder Society Evidence-Based Medicine Committee (2018) International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson’s disease. Mov Disord 33, 1248–1266.29570866)
Fox SH , Katzenschlager R , Lim SY , Barton B , de Bie RMA , Seppi K , Coelho M , Sampaio C ; Movement Disorder Society Evidence-Based Medicine Committee (2018) International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson’s disease. Mov Disord 33, 1248–1266.29570866Fox SH , Katzenschlager R , Lim SY , Barton B , de Bie RMA , Seppi K , Coelho M , Sampaio C ; Movement Disorder Society Evidence-Based Medicine Committee (2018) International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson’s disease. Mov Disord 33, 1248–1266.29570866, Fox SH , Katzenschlager R , Lim SY , Barton B , de Bie RMA , Seppi K , Coelho M , Sampaio C ; Movement Disorder Society Evidence-Based Medicine Committee (2018) International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson’s disease. Mov Disord 33, 1248–1266.29570866
( Marsala SZ , Gioulis M , Ceravolo R , Tinazzi M (2012) A systematic review of catechol-0-methyltransferase inhibitors: efficacy and safety in clinical practice. Clin Neuropharmacol 35, 185–190.22805229)
Marsala SZ , Gioulis M , Ceravolo R , Tinazzi M (2012) A systematic review of catechol-0-methyltransferase inhibitors: efficacy and safety in clinical practice. Clin Neuropharmacol 35, 185–190.22805229Marsala SZ , Gioulis M , Ceravolo R , Tinazzi M (2012) A systematic review of catechol-0-methyltransferase inhibitors: efficacy and safety in clinical practice. Clin Neuropharmacol 35, 185–190.22805229, Marsala SZ , Gioulis M , Ceravolo R , Tinazzi M (2012) A systematic review of catechol-0-methyltransferase inhibitors: efficacy and safety in clinical practice. Clin Neuropharmacol 35, 185–190.22805229
( Hansen RN , Suh K , Serbin M , Yonan C , Sullivan SD (2021) Cost-effectiveness of opicapone and entacapone in reducing OFF-time in Parkinson’s disease patients treated with levodopa/carbidopa. J Med Econ 24, 563–569.33866942)
Hansen RN , Suh K , Serbin M , Yonan C , Sullivan SD (2021) Cost-effectiveness of opicapone and entacapone in reducing OFF-time in Parkinson’s disease patients treated with levodopa/carbidopa. J Med Econ 24, 563–569.33866942Hansen RN , Suh K , Serbin M , Yonan C , Sullivan SD (2021) Cost-effectiveness of opicapone and entacapone in reducing OFF-time in Parkinson’s disease patients treated with levodopa/carbidopa. J Med Econ 24, 563–569.33866942, Hansen RN , Suh K , Serbin M , Yonan C , Sullivan SD (2021) Cost-effectiveness of opicapone and entacapone in reducing OFF-time in Parkinson’s disease patients treated with levodopa/carbidopa. J Med Econ 24, 563–569.33866942
K. Deane, S. Spieker, C. Clarke (2004)
Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease.The Cochrane database of systematic reviews, 4
A. Hsu, Hsuan-Ming Yao, Suneel Gupta, N. Modi (2015)
Comparison of the pharmacokinetics of an oral extended‐release capsule formulation of carbidopa‐levodopa (IPX066) with immediate‐release carbidopa‐levodopa (Sinemet®), sustained‐release carbidopa‐levodopa (Sinemet® CR), and carbidopa‐levodopa‐entacapone (Stalevo®)Journal of Clinical Pharmacology, 55
( Moher D , Liberati A , Tetzlaff J , Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6, e1000097.19621072)
Moher D , Liberati A , Tetzlaff J , Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6, e1000097.19621072Moher D , Liberati A , Tetzlaff J , Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6, e1000097.19621072, Moher D , Liberati A , Tetzlaff J , Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6, e1000097.19621072
(2020)
Estimation of the 2020 global population of Parkinson’s disease (PD) [abstract]
( Higgins JPT , Savović J , Page MJ , Elbers RG , Sterne JAC (2019) Chapter 8: Assessing risk of bias in a randomized trial. In Cochrane Handbook for Systematic Reviews of Interventions, Second Edition, Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, eds. The Cochrane Collaboration.)
Higgins JPT , Savović J , Page MJ , Elbers RG , Sterne JAC (2019) Chapter 8: Assessing risk of bias in a randomized trial. In Cochrane Handbook for Systematic Reviews of Interventions, Second Edition, Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, eds. The Cochrane Collaboration.Higgins JPT , Savović J , Page MJ , Elbers RG , Sterne JAC (2019) Chapter 8: Assessing risk of bias in a randomized trial. In Cochrane Handbook for Systematic Reviews of Interventions, Second Edition, Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, eds. The Cochrane Collaboration., Higgins JPT , Savović J , Page MJ , Elbers RG , Sterne JAC (2019) Chapter 8: Assessing risk of bias in a randomized trial. In Cochrane Handbook for Systematic Reviews of Interventions, Second Edition, Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, eds. The Cochrane Collaboration.
( Hsu A , Yao HM , Gupta S , Modi NB (2015) Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet®), sustained-release carbidopa-levodopa (Sinemet® CR), and carbidopa-levodopa-entacapone (Stalevo®). J Clin Pharmacol 55, 995–1003.25855267)
Hsu A , Yao HM , Gupta S , Modi NB (2015) Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet®), sustained-release carbidopa-levodopa (Sinemet® CR), and carbidopa-levodopa-entacapone (Stalevo®). J Clin Pharmacol 55, 995–1003.25855267Hsu A , Yao HM , Gupta S , Modi NB (2015) Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet®), sustained-release carbidopa-levodopa (Sinemet® CR), and carbidopa-levodopa-entacapone (Stalevo®). J Clin Pharmacol 55, 995–1003.25855267, Hsu A , Yao HM , Gupta S , Modi NB (2015) Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet®), sustained-release carbidopa-levodopa (Sinemet® CR), and carbidopa-levodopa-entacapone (Stalevo®). J Clin Pharmacol 55, 995–1003.25855267
( Haasio K (2010) Toxicology and safety of COMT inhibitors. Int Rev Neurobiol 95, 163–189.21095462)
Haasio K (2010) Toxicology and safety of COMT inhibitors. Int Rev Neurobiol 95, 163–189.21095462Haasio K (2010) Toxicology and safety of COMT inhibitors. Int Rev Neurobiol 95, 163–189.21095462, Haasio K (2010) Toxicology and safety of COMT inhibitors. Int Rev Neurobiol 95, 163–189.21095462
( Thanvi B , Lo N , Robinson T (2007) Levodopa-induced dyskinesia in Parkinson’s disease: clinical features, pathogenesis, prevention and treatment. Postgrad Med J 83, 384–388.17551069)
Thanvi B , Lo N , Robinson T (2007) Levodopa-induced dyskinesia in Parkinson’s disease: clinical features, pathogenesis, prevention and treatment. Postgrad Med J 83, 384–388.17551069Thanvi B , Lo N , Robinson T (2007) Levodopa-induced dyskinesia in Parkinson’s disease: clinical features, pathogenesis, prevention and treatment. Postgrad Med J 83, 384–388.17551069, Thanvi B , Lo N , Robinson T (2007) Levodopa-induced dyskinesia in Parkinson’s disease: clinical features, pathogenesis, prevention and treatment. Postgrad Med J 83, 384–388.17551069
I. Katsaiti, J. Nixon (2018)
Are There Benefits in Adding Catechol-O Methyltransferase Inhibitors in the Pharmacotherapy of Parkinson's Disease Patients? A Systematic Review.Journal of Parkinson's disease, 8 2
A. Lees, J. Ferreira, O. Rascol, W. Poewe, J. Rocha, M. McCrory, P. Soares-da-Silva (2017)
Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical TrialJAMA Neurology, 74
J. Rivest, C. Barclay, O. Suchowersky (1999)
COMT Inhibitors in Parkinson's DiseaseCanadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 26
D. Moher, A. Liberati, J. Tetzlaff, D. Altman (2009)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA StatementPLoS Medicine, 6
Thanvi (2007)
Levodopa-induced dyskinesia in Parkinson’s disease: clinical features, pathogenesis, prevention and treatmentPostgrad Med J, 83
M. Fabbri, J. Ferreira, A. Lees, F. Stocchi, W. Poewe, E. Tolosa, O. Rascol (2018)
Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicineMovement Disorders, 33
T. Pringsheim, N. Jetté, A. Frolkis, T. Steeves (2014)
The prevalence of Parkinson's disease: A systematic review and meta‐analysisMovement Disorders, 29
R. Hansen, K. Suh, M. Serbin, C. Yonan, S. Sullivan (2021)
Cost-effectiveness of opicapone and entacapone in reducing OFF-time in Parkinson’s disease patients treated with levodopa/carbidopaJournal of Medical Economics, 24
( Lee JJ (2019) Pharmacological treatment in Parkinson’s disease. J Korean Neurol Assoc 37, 335–344.)
Lee JJ (2019) Pharmacological treatment in Parkinson’s disease. J Korean Neurol Assoc 37, 335–344.Lee JJ (2019) Pharmacological treatment in Parkinson’s disease. J Korean Neurol Assoc 37, 335–344., Lee JJ (2019) Pharmacological treatment in Parkinson’s disease. J Korean Neurol Assoc 37, 335–344.
( Pringsheim T , Jette N , Frolkis A , Steeves TD (2014) The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord 29, 1583–1590.24976103)
Pringsheim T , Jette N , Frolkis A , Steeves TD (2014) The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord 29, 1583–1590.24976103Pringsheim T , Jette N , Frolkis A , Steeves TD (2014) The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord 29, 1583–1590.24976103, Pringsheim T , Jette N , Frolkis A , Steeves TD (2014) The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord 29, 1583–1590.24976103
M. Feldman, J. Margolesky (2021)
Opicapone for the treatment of Parkinson’s disease: a reviewInternational Journal of Neuroscience, 133
( Salamon A , Zádori D , Szpisjak L , Klivényi P , Vécsei L (2019) Opicapone for the treatment of Parkinson’s disease: an update. Expert Opin Pharmacother 20, 2201–2207.31670988)
Salamon A , Zádori D , Szpisjak L , Klivényi P , Vécsei L (2019) Opicapone for the treatment of Parkinson’s disease: an update. Expert Opin Pharmacother 20, 2201–2207.31670988Salamon A , Zádori D , Szpisjak L , Klivényi P , Vécsei L (2019) Opicapone for the treatment of Parkinson’s disease: an update. Expert Opin Pharmacother 20, 2201–2207.31670988, Salamon A , Zádori D , Szpisjak L , Klivényi P , Vécsei L (2019) Opicapone for the treatment of Parkinson’s disease: an update. Expert Opin Pharmacother 20, 2201–2207.31670988
A. Gordin, S. Kaakkola, H. Teräväinen (2004)
Clinical advantages of COMT inhibition with entacapone – a reviewJournal of Neural Transmission, 111
( LeWitt PA (2015) Levodopa therapy for Parkinson’s disease: Pharmacokinetics and pharmacodynamics. Mov Disord 30, 64–72.25449210)
LeWitt PA (2015) Levodopa therapy for Parkinson’s disease: Pharmacokinetics and pharmacodynamics. Mov Disord 30, 64–72.25449210LeWitt PA (2015) Levodopa therapy for Parkinson’s disease: Pharmacokinetics and pharmacodynamics. Mov Disord 30, 64–72.25449210, LeWitt PA (2015) Levodopa therapy for Parkinson’s disease: Pharmacokinetics and pharmacodynamics. Mov Disord 30, 64–72.25449210
Lees (2008)
Evidence-based efficacy comparison of tolcapone and entacapone as adjunctive therapy in Parkinson’s diseaseCNS Neurosci Ther, 14
( Martinez-Martin P , O’Brien C (1998) Extending levodopa action: COMT inhibition. Neurology 50, S27–S32.)
Martinez-Martin P , O’Brien C (1998) Extending levodopa action: COMT inhibition. Neurology 50, S27–S32.Martinez-Martin P , O’Brien C (1998) Extending levodopa action: COMT inhibition. Neurology 50, S27–S32., Martinez-Martin P , O’Brien C (1998) Extending levodopa action: COMT inhibition. Neurology 50, S27–S32.
( EMEA (2004) European Medicines Agency Public Statement on the lifting of the suspension of the marketing authorisation for Tolcapone (Tasmar).)
EMEA (2004) European Medicines Agency Public Statement on the lifting of the suspension of the marketing authorisation for Tolcapone (Tasmar).EMEA (2004) European Medicines Agency Public Statement on the lifting of the suspension of the marketing authorisation for Tolcapone (Tasmar)., EMEA (2004) European Medicines Agency Public Statement on the lifting of the suspension of the marketing authorisation for Tolcapone (Tasmar).
( Song Z , Zhang J , Xue T , Yang Y , Wu D , Chen Z , You W , Wang Z (2021) Different catechol-O-methyl transferase inhibitors in Parkinson’s disease: a Bayesian network meta-analysis. Front Neurol 12, 707723.34630283)
Song Z , Zhang J , Xue T , Yang Y , Wu D , Chen Z , You W , Wang Z (2021) Different catechol-O-methyl transferase inhibitors in Parkinson’s disease: a Bayesian network meta-analysis. Front Neurol 12, 707723.34630283Song Z , Zhang J , Xue T , Yang Y , Wu D , Chen Z , You W , Wang Z (2021) Different catechol-O-methyl transferase inhibitors in Parkinson’s disease: a Bayesian network meta-analysis. Front Neurol 12, 707723.34630283, Song Z , Zhang J , Xue T , Yang Y , Wu D , Chen Z , You W , Wang Z (2021) Different catechol-O-methyl transferase inhibitors in Parkinson’s disease: a Bayesian network meta-analysis. Front Neurol 12, 707723.34630283
J. Ferreira, A. Lees, J. Rocha, W. Poewe, O. Rascol, P. Soares-da-Silva (2016)
Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trialThe Lancet Neurology, 15
P. LeWitt (2015)
Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamicsMovement Disorders, 30
L. Scott (2016)
Opicapone: A Review in Parkinson’s DiseaseDrugs, 76
( Simon DK , Tanner CM , Brundin P (2020) Parkinson disease epidemiology, pathology, genetics, and pathophysiology. Clin Geriatr Med 36, 1–12.31733690)
Simon DK , Tanner CM , Brundin P (2020) Parkinson disease epidemiology, pathology, genetics, and pathophysiology. Clin Geriatr Med 36, 1–12.31733690Simon DK , Tanner CM , Brundin P (2020) Parkinson disease epidemiology, pathology, genetics, and pathophysiology. Clin Geriatr Med 36, 1–12.31733690, Simon DK , Tanner CM , Brundin P (2020) Parkinson disease epidemiology, pathology, genetics, and pathophysiology. Clin Geriatr Med 36, 1–12.31733690
K. Haasio (2010)
Toxicology and safety of COMT inhibitors.International review of neurobiology, 95
P. Martínez-Martín, C. O’Brien (1998)
Extending levodopa actionNeurology, 50
A. Lees (2008)
Evidence‐Based Efficacy Comparison of Tolcapone and Entacapone as Adjunctive Therapy in Parkinson's DiseaseCNS Neuroscience & Therapeutics, 14
András Salamon, D. Zádori, L. Szpisjak, P. Klivényi, L. Vécsei (2019)
Opicapone for the treatment of Parkinson’s disease: an updateExpert Opinion on Pharmacotherapy, 20
Background:Long-term levodopa administration for treating Parkinson’s disease (PD) may shorten the duration of effect and cause dyskinesias, inducing the need for catechol-O-methyltransferase (COMT) inhibitors as adjuvant therapy.Objective:We provide pooled scientific evidence highlighting the efficacy and safety of opicapone, a newly approved COMT inhibitor, as an adjuvant to levodopa.Methods:We searched Ovid Medline, Embase, and Cochrane databases for relevant reports. Efficacy and safety were evaluated as off-time reduction and risk ratio (RR) of dyskinesia, respectively. Data were independently extracted using predefined criteria. Selected placebo-controlled trials were divided into double-blind and open-label periods. Using a random-effects model, the mean difference (MD) of the off-time reduction (efficacy), RR for the occurrence of dyskinesia, and on-time without/with troublesome dyskinesia (TD; safety assessment) were compared between opicapone and placebo groups.Results:Five studies from three randomized controlled trials were included, and a meta-analysis was performed with 407 patients receiving opicapone 50 mg and 402 patients receiving placebo. Compared with the placebo, opicapone (50 mg) reduced off-time by 49.91 min during the double-blind period (95% confidence intervals [CIs] = –71.39, –28.43; I2 = 0%). The RR of dyskinesia was 3.43 times greater in the opicapone 50 mg group than in the placebo group (95% CI = 2.14, 5.51; I = 0%). Compared with the placebo, opicapone increased the on-time without TD by 44.62 min (95% CI = 22.60, 66.64; I2 = 0%); the on-time increase with TD did not differ between treatments.Conclusion:Opicapone can play a positive role as an adjuvant to levodopa in patients with PD by reducing off-time and prolonging on-time without PD.
Journal of Parkinson's Disease – IOS Press
Published: Apr 5, 2022
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.